Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05760-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Akriti G Jain und 12 weiteren Autor:innen. Beteiligte Einrichtung: Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue CA-60,, Cleveland, OH, 44195, USA. Jaina9@ccf.org. Hauptthemen laut MEDLINE: Dasatinib, Protein Kinase Inhibitors, Pleural Effusion. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Dasatinib is one of the second generation tyrosine kinase inhibitors (TKI) which is approved for the treatment of patients with chronic phase CML (CP-CML) both in the front line and in the second line setting. Pleural effusion (PE) is a unique toxicity associated with dasatinib use. Our aim was to study the incidence of pleural effusion in our cohort of patients who were treated with dasatinib for CP-CML and the safety upon TKI switch. A total of 390 patients were treated with dasatinib during their course of treatment for CP-CML. A total of 69 patients (17.6%) developed any grade of PE. About 33 (48%) patients developed CTCAE grade 2 PE, 34 (49%) grade 3 and only 1 patient developed grade 4 PE. Recurrence of PE was observed in 34 (49%) patients. While only 12 patients (17.3%) continued using dasatinib after development of PE, dasatinib was discontinued in the other 57 patients. Therapy was switched to bosutinib in 13 patients out of which 6 (46%) patients re-developed PE. While only 12.5% patients developed re-accumulation of pleural fluid in patients switched to imatinib, none of the patients switched to nilotinib re-developed PE. A change in TKI to bosutinib was associated with a 46% risk of recurrence of PE in patients who develop PE on dasatinib for the treatment of CP-CML. The incidence of recurrent PE was markedly lower in patient switched to imatinib or nilotinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue CA-60,, Cleveland, OH, 44195, USA. Jaina9@ccf.org.
- Hematology Oncology Fellow, Thomas Jefferson University, Philadelphia, PA, USA.
- Vanderbilt University Medical Center, Nashville, TN, USA.
- Division of Malignant Hematology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Zitieren
APA
Jain, A. G., Gesiotto, Q., Ball, S., Nodzon, L., Rodriguez, A., Chan, O., Padron, E., Kuykendall, A., Komrokji, R., Sallman, D. A., Lancet, J. E., Pinilla-Ibarz, J., & Sweet, K. (2024). Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML. Annals of Hematology. https://doi.org/10.1007/s00277-024-05760-6
Vancouver
Jain AG, Gesiotto Q, Ball S, Nodzon L, Rodriguez A, Chan O, et al. Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML. Annals of Hematology. 2024. doi:10.1007/s00277-024-05760-6
BibTeX
@article{Jain2024,
author = {Jain, Akriti G and Gesiotto, Quinto and Ball, Somedeb and Nodzon, Lisa and Rodriguez, Amanda and Chan, Onyee and Padron, Eric and Kuykendall, Andrew and Komrokji, Rami and Sallman, David A and Lancet, Jeffrey E and Pinilla-Ibarz, Javier and Sweet, Kendra},
title = {Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05760-6}
}
EUVIMED